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Homogeneous MGMT immunoreactivity correlates with an
unmethylated MGMT promoter status in brain metastases of
various solid tumors
Abstract
The O(6)-methylguanine-methyltransferase (MGMT) promoter methylation status is a predictive
parameter for the response of malignant gliomas to alkylating agents such as temozolomide. First
clinical reports on treating brain metastases with temozolomide describe varying effects. This may be
due to the fact that MGMT promoter methylation of brain metastases has not yet been explored in depth.
Therefore, we assessed MGMT promoter methylation of various brain metastases including those
derived from lung (n = 91), breast (n = 72) kidney (n = 49) and from malignant melanomas (n = 113) by
methylation-specific polymerase chain reaction (MS-PCR) and MGMT immunoreactivity. Fifty-nine of
199 brain metastases (29.6%) revealed a methylated MGMT promoter. The methylation rate was the
highest in brain metastases derived from lung carcinomas (46.5%) followed by those from breast
carcinoma (28.8%), malignant melanoma (24.7%) and from renal carcinoma (20%). A significant
correlation of homogeneous MGMT-immunoreactivity (>95% MGMT positive tumor cells) and an
unmethylated MGMT promoter was found. Promoter methylation was detected in 26 of 61 (43%)
tumors lacking MGMT immunoreactivity, in 17 of 63 (27%) metastases with heterogeneous MGMT
expression, but only in 5 of 54 brain metastases (9%) showing a homogeneous MGMT
immunoreactivity. Our results demonstrate that a significant number of brain metastases reveal a
methylated MGMT-promoter. Based on an obvious correlation between homogeneous MGMT
immunoreactivity and unmethylated MGMT promoter, we hypothesize that immunohistochemistry for
MGMT may be a helpful diagnostic tool to identify those tumors that probably will not benefit from the
use of alkylating agents. The discrepancy between promoter methylation and a lack of MGMT
immunoreactivity argues for assessing MGMT promoter methylation both by immunohistochemical as
well as by molecular approaches for diagnostic purposes.
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Introduction
O6-methylguanine-methyltransferase (MGMT) is a DNA
repair protein which catalyzes the transfer of the methyl group
from O6-methylguanine to a cysteine residue of its active site [1].
In this single step reaction, DNA-lesions caused by alkylating
substances are repaired. MGMT subsequently is ubiquitylated
and degraded [2]. Therefore, the cellular activity of MGMT is
directly linked to the expression level of the protein. The high
DNA repair activity of tumor cells expressing active MGMT is
believed to defend the tumor from the cytotoxic effects of
alkylating agents [3,4]. Tumors with low or no levels of MGMT
due to epigenetic silencing of MGMT by methylation of CpG
islands in the promoter region may predictably be responsive to
such therapy [5]. Chemotherapy-induced lesions remain un-
repaired and trigger cytotoxicity and apoptosis, which is the
desired outcome. In several studies the correlation of MGMT
promoter methylation status and the response of tumors to
alkylating agents (e.g. carmustin, lomustine, temozolomide) has
been examined [5–7]. For example patients suffering from
glioblastoma multiforme with a methylated MGMT promoter
had a better outcome after therapy with temozolomide (TMZ)
than those patients, without a methylated MGMT promoter.
This supports the hypothesis that MGMT inactivation by
aberrant promoter methylation correlates with the sensitivity of
the tumor to alkylating agents [7].
The most common intracranial neoplasms of the adult are
metastases originating from primary systemic neoplasms [8]. The
most frequent primary sources of brain metastases are carcinomas
of the respiratory tract (50%) and breast (15%) followed by
malignant melanomas (10.5%) [8]. Brain metastases of renal
cancer have been reported in up to 5%. In about 10% the
metastatic origin remains unknown. A broad range of incidence
and prevalence is reported for all types of brain metastases, since
calculations are based on assorted epidemiologic, autoptic and
clinical studies [9].
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The ability to effectively treat brain metastases, however,
remains poor. Surgery is limited due to the delicate structure of the
human brain which excludes functionally important areas of
resection, and the risk of neurotoxic side effects, especially in
elderly patients and children, limits the tolerance of radiation [10].
So far, chemotherapy had played a minor role in the treatment of
brain metastases and its profit is yet not fully defined. The blood-
brain-barrier has been the major obstacle to successfully deliver
active chemotherapeutic agents. Moreover, the limited benefit
derived from chemotherapy is associated with severe side effects
[11]. TMZ is an orally administered alkylating agent that plays an
important role in the standard therapy of malignant gliomas. It has
a good blood-brain-barrier penetration which results in therapeu-
tic concentrations within the central nervous system (CNS) and
confers manageable side effects. The possible role of TMZ in the
treatment of brain metastases is currently being explored. Several
studies on utilizing TMZ in patients with brain metastases describe
rather variable outcomes [12]. Although MGMT promoter
methylation is known to be a predictive factor for the success of
using alkylating substances like TMZ in malignant gliomas [4,5,7],
MGMT promoter methylation of brain metastases has not been
explored in depth.
Most studies on MGMT promoter methylation rely on the
methylation-specific polymerase chain reaction assay (MS-PCR)
[5,7,13]. Other investigators prefer the somewhat simpler
approach to detect the function of the MGMT gene by means
of immunhistochemistry [14–16]. However, data addressing both,
MGMT promoter methylation and MGMT immunoreactivity,
are sparse and controversially discussed [17–19]. Consequently,
we aimed here to investigate comprehensively MGMT promoter
methylation and MGMT immunohistochemistry in brain metas-




Formalin-fixed, paraffin-embedded tissue samples of 325 brain
metastases were subjected for MGMT promoter methylation
analysis and immunohistochemical analysis comprising brain
metastases of carcinomas of the lung (n= 91), the breast (n = 72)
and the kidney (n= 49, clear cell renal cell carcinoma) as well as
malignant melanoma (n= 113). Brain metastases were derived
from the Institute of Neuropathology, University of Zurich (1981–
2005). All tumor samples have been re-evaluated systematically by
one neuropathologist (FLH). This project has been approved by
the local ethics committee (ref. number StV 37-2005).
DNA extraction and methylation-specific PCR
Genomic DNA was isolated from two to three 20 mm thick
paraffin sections by the EZ1 DNA tissue kit (Qiagen) using the
BioRobot EZ1 workstation (Qiagen). Sodium bisulfite modifica-
tion of isolated DNA was performed using the Zymo research EZ
DNA Methylation kit (Zymo Research, Orange, CA, USA). The
analysis of the methylation status of the MGMT gene was done
in a nested, two stage PCR approach basically as reported by
Palmisano and colleagues [13]. DNA of normal lymphocytes was
used as negative control for methylated alleles of MGMT, and
DNA of the cell-line SW620 (human colorectal adenocarcinoma;
American Type Culture Collection) was used as positive control
for methylated alleles of MGMT. PCR products were analyzed
by electrophoresis in 2.5% agarose gel containing ethidium
bromide.
Tissue microarray construction
Formalin-fixed, paraffin-embedded tissue samples were used to
generate tissue microarrays (TMA) as described previously [20–
23]. A morphologically representative region of the paraffin
‘donor’ block was chosen. Tissue cylinders were punched from this
area (diameter: 0.6 mm) and precisely arrayed into a new
‘recipient’ paraffin block using a customer built instrument. After
completing the block construction, four micrometer sections of the
resulting tumor tissue microarray block were cut for further
analysis.
Immunohistochemistry
Immunohistochemistry was performed using the BondTM
automated staining system (Vision BioSystems, Newcastle Upon
Tyne, UK). Sections were incubated with an antibody against the
human MGMT (dilution: 1:160; monoclonal mouse IgG1; clone
MT3.1; NeoMarkers, Newmarket, UK). For antigen retrieval,
slides were pre-treated with the BondTM Epitope Retrieval
Solution 2 (Vision BioSystems). Endogenous biotin was blocked
with the appropriate kit. Slides were incubated with the BondTM
Polymer Refine Detection kit (Vision BioSystems). Slides were
counterstained with hematoxylin prior to glass coverslipping.
MGMT-immunopositive cells revealed a strong nuclear staining.
Lymphocytes and endothelial cells served as internal positive
control. The immunoreactivity was scored semi-quantitatively as
follows: 0: ,5% positive tumor cells, 1+: 5–75% positive tumor
cells, 2+: 75–95% positive tumor cells, 3+: .95% positive tumor
cells. 3+ scores were designated as a homogeneous MGMT
expression. Only a nuclear staining was regarded as positive.
Colon carcinoma tissue served as positive control.
Statistical analyses
Contingency table analysis and Chi-square tests were applied
for evaluating correlations between MGMT immunoreactivity and
promoter methylation using SPSS 15.0 for Windows (SPSS Inc.,




An appropriate amount of DNA with sufficient quality needed
for bisulfite conversion could be isolated from 246 of 325 brain
metastases (75.7%). DNA was available from brain metastases of
lung (n= 63), breast (n = 51), renal cancer (n = 34) and malignant
melanoma (n= 98). MGMT methylation status could be deter-
mined for 199 of 246 (80.9%) samples. Overall, a methylated
MGMT promoter was detectable in 59 of 199 (29.6%) of the
metastases by MS-PCR. The frequencies of methylated and
unmethylated MGMT promoter in the 4 tumor subgroups is
shown in figure 1. No subtype specific MGMT promoter
methylation differences were detected in brain metastases deriving
from lung (squamous cell carcinoma (3), small cell carcinoma (4),
adenocarcinoma (16), large cell carcinoma (1), neuroendocrine
tumours (2), poorly differentiated (8), NOS (9)) and breast
carcinoma (invasive ductal (9), neuroendocrine tumors (2),
mucinous carcinoma (1), poorly differentiated (6), NOS (27)).
MGMT protein expression
MGMT-immunoreactivity was assessed of 285 brain metastases
using a tissue microarray (77 lung carcinomas, 62 breast
carcinomas, 42 renal cell carcinomas, 104 malignant melanomas).
96 of 285 (33.7%) tumor samples revealed a homogeneous
MGMT expression (.95% MGMT-immunopositive tumor cells),
MGMT in Brain Metastases
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whereas 91 of 285 (31.8%) lacked immunoreactivity for MGMT. In
98 cases (34.4%) a heterogeneous tumor population (1+ and 2+) was
detectable consisting of MGMT-immunopositive and negative
tumor cells. Examples are shown in figure 2a–c. The MGMT
immunoreactivity pattern in the different tumor subgroups is shown
in table 1. The fractions of 0 and 3+ samples varied significantly
between the 4 tumor subtypes (table 2). 3+ samples were most
frequent in breast and lung carcinoma metastases (46.8% and
42.6% respectively) whereas more than 45% of renal cell carcinoma
and melanoma brain metastases were MGMT negative.
MGMT expression and MGMT promoter methylation
status
Methylation status of the MGMT promoter as assessed by MS-
PCR as well as the MGMT immunoprofile was available from 178
tumor samples (27 metastases of renal cell carcinoma, 39 of breast
carcinoma, 36 of lung carcinoma, and 76 of malignant
melanoma). There was a significant correlation between homoge-
neous MGMT-positivity and an unmethylated MGMT promoter.
Forty-nine of 54 (90.7%) brain metastases displaying a homoge-
neous MGMT immunoreactivity revealed an unmethylated
MGMT promoter. 21 of 28 (75%) brain metastases with a 1+
score and 25 of 35 (71.4%) brain metastases with a 2+ score had
an unmethylated MGMT promoter. However, only 26 of 61 brain
metastases (42.6%) lacking MGMT-immunoreactivity showed a
methylated MGMT promoter. MGMT methylation frequencies in
MGMT 3+, 2+, 1+ and 0 brain metastases are shown in figure 3.
A separate analysis of the individual tumor subgroups generally
confirmed that MGMT immunopositivity correlates with an
unmethylated MGMT promoter. The frequencies of tumors with
a homogeneous MGMT staining and an unmethylated promoter
ranged between 100% (7 of 7 clear cell renal cell carcinomas) and
86% (12 of 14 lung carcinomas). In contrast MGMT promoter
methylation and lack of MGMT reactivity ranged between 67% (2
of 3 breast cancer) and 32% (11 of 34 melanomas). The detailed
frequencies of MGMT reactivity and promoter methylation status
in all tumor subgroups is shown in table 3.
Discussion
In this study, we demonstrate that about 30% of brain
metastases originating from renal, breast and lung cancer as well
as from malignant melanomas reveal a methylated MGMT-
promoter. We found a strong correlation between a homogeneous
MGMT expression pattern and an unmethylated MGMT
promoter. In contrast MGMT negative brain metastases only in
42.6% showed a methylated MGMT promoter.
The therapeutic strategy to treat brain metastases depends on the
patients’ performance status, systemic tumor activity and the negative
impact of older age. Treatment with surgery, radiosurgery and whole
brain radiation therapy (WBRT) are the first line therapies for the
majority of patients [11]. Although chemotherapy as a single
modality has demonstrated limited efficacy, it may improve the
Figure 1. Frequencies of unmethylated and methylated MGMT
promoter in the 4 tumor subgroups.
doi:10.1371/journal.pone.0004775.g001
Figure 2. (a) Brain metastasis of a melanoma lacking MGMT
immunoreactivity. MGMT-immunopositive endothelial cells and leuko-
cytes served as internal positive control (arrow). (b) HeterogeneousMGMT
immunoreactivity revealing MGMT-positive tumor cells intermingled with
MGMT negative tumor cells (breast carcinoma). (c) Strong nuclear reaction
for MGMT in all tumor cells (lung carcinoma). Scale bar: a–c: 100 mm.
doi:10.1371/journal.pone.0004775.g002
MGMT in Brain Metastases
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result as a concurrent treatment [11]. Overall, there is only limited
data on chemotherapeutic protocols from which no firm treatment
recommendation can be drawn. Treatment efficacy is determined by
the sensitivity of tumor cells to chemotherapeutic agents. Therefore,
the chemotherapeutic regimen with highest efficacy to fight the
primary tumor in principle is considered also to be the most
efficacious for the corresponding brain metastasis [24]. In general,
malignant melanoma, renal cell carcinoma and NSCLC show a fairly
low chemosensitivity, whereas breast cancer reveal a moderately,
SCLC and germ cell cancers a rather high chemosensitivity [11].
The role of TMZ in the treatment of brain metastases is still
unclear. Several studies on treating brain metastases with TMZ
alone showed low response rates. Preliminary results from
randomized trials suggest that combination of TMZ and WBRT
is an effective option for patients with brain metastases of non small
cell lung cancer [25]. In malignant melanoma, a reduction of
mortality from 69% to 41% was observed [26]. For patients with
breast cancer [11] and renal cell carcinoma brain metastases [27],
TMZ seems to be less helpful. An obvious possible explanation for
variable TMZ efficacy in treating brain metastases is that MGMT
promoter methylation has not been investigated systematically in
brain metastases [28]. Thus, similarly as for malignant gliomas,
where epigenetic silencing of the MGMT gene by promoter
methylation has been shown to be of predictive value for profiting
from TMZ [4,5,7], TMZ efficacy needs to be correlated to the
MGMT promoter methylation status in individual brain metastases.
In this study, we show that about one third of brain metastases
revealed a methylated MGMT promoter (29.6%; 59 of 199). The
methylation rate in the different tumor subgroups (lung, breast,
renal carcinoma and malignant melanoma) ranged between 20%
and 46.5%. These results are in line with a previous study on a
rather limited number of brain metastases (n = 28) resulting in
promoter methylation in ,36% [29].
Most studies assessing MGMT promoter methylation status
utilize MS-PCR, which is a cost-efficient method requiring only
small quantities of DNA. However, DNA derived from FFPE-
tissue – the routine approach to process tissue for histological
assessment and archiving - has been reported to be more often
degraded, thus limiting the validity of molecular analyses. On top,
bisulfite treatment – a prerequisite for MGMT promoter
methylation assays - introduces various additional DNA strand
Table 1. MGMT immunoreactivity scores in the 4 tumor
subgroups.
Tumor entity Cases (n) MGMT immunoreactivity n (%)
3+ 2+ 1+ 0
Renal cell carcinoma 42 11 (26) 7 (17) 4 (10) 20 (47)
Breast carcinoma 62 29 (47) 17 (27) 12 (19) 4 (7)
Lung carcinoma 77 33 (43) 11 (14) 13 (17) 20 (26)
Malignant melanoma 104 23 (22) 15 (15) 19 (18) 47 (45)
doi:10.1371/journal.pone.0004775.t001
Table 2. Differences between fractions of tumors with
homogeneous (3+) and negative MGMT immunoreactivity in





Renal cell carcinoma p,0.0001 p,0.025 n.s.
Breast carcinoma p,0.025 p,0.0001
Lung carcinoma p,0.01
doi:10.1371/journal.pone.0004775.t002
Figure 3. MGMT immunoreactivity and promoter methylation
status in brain metastases. The fractions of brain metastases with
unmethylated and methylated MGMT promoter differ significantly in 3+
versus 0 (p,0.001) and in 3+ versus 2+ (p = 0.0174) tumors.
doi:10.1371/journal.pone.0004775.g003
Table 3. MGMT immunoreactivity and promoter methylation status in the individual tumor subgroups of brain metastases.
Tumor entity MGMT promoter methylation status Cases (n) MGMT immunoreactivity, n (%)
3+ 2+ 1+ 0
Renal cell carcinoma methylated 6 0 0 0 6 (100)
unmethylated 21 7 (33) 6 (29) 1(5) 7 (33)
Breast carcinoma methylated 10 2 (20) 5 (50) 1 (10) 2 (20)
unmethylated 29 16 (55) 8 (28) 4 (14) 1 (3)
Lung carcinoma methylated 14 2 (14) 3 (22) 2 (14) 7 (50)
unmethylated 22 12 (55) 2 (9) 4 (18) 4 (18)
Malignant melanoma methylated 18 1(6) 2 (11) 4 (23) 11 (60)
unmethylated 58 14 (24) 9 (16) 12 (21) 23 (39)
MGMT immunoreactivity and promoter methylation status were significantly associated in renal cell carcinoma (p,0.05), breast carcinoma (p,0.05) and lung carcinoma
(p,0.025). A similar trend was seen in melanoma (p.0.05).
doi:10.1371/journal.pone.0004775.t003
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breaks resulting in highly fragmented single stranded DNA [30].
Detection of the MGMT methylation status by 80 cycles of a
nested PCR, as recommended for DNA isolated from formalin-
fixed paraffin-embedded tissue [13], may easily increase the
frequency of sampling error, thus negatively influencing the
reliability of results obtained by MS-PCR. This may explain as to
why only 61.2% (199 of 325) of our samples were evaluable by
MS-PCR and why only in 75% of the cases replicate experiments
on 20 randomly selected tumor samples yielded reproducible
results. Despite such limitations MS-PCR on FFPE has been
shown to be a valid and trustable technique resulting in
reproducible data, which closely mirrors results obtained by MS-
PCR on fresh frozen tissue [31].
High levels of endogenous MGMT in tumor cells are believed to
protect the tumor from alkylating agents used in chemotherapeutic
regimen and MGMT levels may be an important parameter of
treatment failure. Therefore, some investigators prefer the somewhat
simpler immunohistochemical approach to detect the expression of
the MGMT protein [14–16]. Compared to MS-PCR, immunohis-
tochemistry is a more reliable method if only FFPE tissue is available.
However, the relevance of MGMT-immunoreactivity is a matter of
intense discussion especially when MGMT-immunoreactivity is
correlated to MGMT promoter methylation status [17–19,32,33].
We therefore evaluated 285 brain metastases for MGMT expression
by immunohistochemistry. In about one third of the cases more than
95% of the tumor cells were MGMT-immunopositive, whereas in
one third no immunoreactivity was detectable. The remaining cases
showed a heterogeneous MGMT-immunoprofile ranging from 5 to
95%. In 178 cases, MS-PCR and immunohistochemical data was
available. We found a strong correlation between homogeneous
MGMT-immunoreactivity and unmethylated MGMT promoter.
MGMT-immunoreactivity and evidence of promoter methylation in
9% of the samples may reflect differences in the methylation status of
the MGMT promoter in tumor cell subpopulations as it is reported
for malignant melanoma [34].
Furthermore, extensive MGMT promoter methylation has been
shown to go along with MGMT gene expression under certain
conditions [35]. A negative MGMT-immunostaining, however,
was not correlated with a defined promoter methylation status,
possibly because methylation of the MGMT promoter is not
necessarily linked to MGMT protein expression. Other mecha-
nisms of gene silencing including gene deletion or mutation may
lead to loss of protein expression - with or without promoter
methylation. Moreover, MGMT is an inducible protein [33,36,37]
and lack of immunoreactivity at time of diagnosis might not reflect
the potential functionality of the protein.
MS-PCR proposes a clear MGMT promoter methylation status
and divides the tumor samples into PCR-positive and –negative cases.
However, the regulation of MGMT expression is a more complex
phenomenon in which methylation of the promoter is not the only
determining factor [38,39]. For instance, in in vitro experiments wild-
type p53 seems to act as an inhibitor of MGMT expression,
suggesting tumors with normal p53 would have more likely low or
absent MGMT levels, independent of promoter methylation. On the
other hand it has been suggested that mutant p53 may be associated
with a decreased MGMT expression and/or methylation [40,41].
Given the different relevance of p53 alterations in melanoma or
breast, lung and renal cancer, such mechanisms may explain the
tumor type-specific differences of MGMT immunoreactivity between
these tumors (table 2). Assessing the protein, e.g. by immunohis-
tochemistry, bypasses several of the above-mentioned pitfalls.
There are at least a few studies on malignant gliomas which
corroborate that MGMT-immunoreactivity is associated with
survival and/or response to alkylating substances [14–16,42,43].
For example, patients with high MGMT expression were reported
to have a lower response rate when receiving TMZ before
radiotherapy. Based on such reports one may hypothesize that
MGMT-immunoreactivity may be a negative predictor of
treatment success with alkylating substances. However, the extent
to which MGMT influences the treatment of brain metastases with
alkylating agents needs to be explored in future studies.
In conclusion, we demonstrate that about one third of brain
metastases of various origins revealed a methylated MGMT
promoter as assessed by MS-PCR assay. This suggests that brain
metastases may be a potential target for therapy with alkylating
substances. Showing a clear correlation between homogeneous
MGMT immunoreactivity and an unmethylated MGMT pro-
moter, we hypothesize that MGMT immunohistochemistry – as a
screening method - could be a helpful diagnostic tool to identify
those tumors that probably will not benefit from the use of
alkylating agents like temozolomide. Clinical data is necessary to
validate this hypothesis. However, the discrepancy between
promoter methylation and MGMT negativity necessitates com-
bined immunostaining and methylation specific PCR.
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